Press Release

Top 5 Players Shaping the Future of Apheresis Market
April 2021

Top 5 Players Shaping the Future of Apheresis Market

NIH defines Apheresis as a procedure of collecting blood, separating its components such as platelets or white blood cells and returning the remainder of blood to the patient. When the procedure is performed for patients, one of the blood components is withdrawn when it is affected by a disease, and the rest of the blood is re-transfused back to the patient. Today, apheresis donation is an important part of treatment for patients with cancer, organ transplant, traumatic injuries and other life-threatening medical conditions. There are a variety of indications for apheresis including hematologic, neurologic and transplant-related indications. Few examples of apheresis techniques are plasmapheresis (removal of plasma), leukapheresis (removal of white blood cells), plateletpheresis (removal of platelets) and erythrocytapheresis (removal of erythrocytes). According to the American Red Cross data, every two seconds someone in the U.S. needs blood. Around 10,000 units of plasma and 7,000 units of platelets are required in the U.S. daily. These statistics clearly indicate the demand for apheresis procedures in the U.S.

The global apheresis market was valued at USD 1,786.9 million in 2019 and is expected to reach USD 2,879.3 million by 2025. Rising prevalence of chronic diseases, increasing demand for blood plasma and platelets and new indication approvals for apheresis treatment method are factors propelling the market growth. Furthermore, the rising cases of COVID-19 pandemic has generated a huge demand for donor plasma for the treatment of this viral infection. However, the market growth is challenged by high installation costs of apheresis devices and shortage of highly skilled expertise that is essential to run these procedures.

Below mentioned are some of the leading companies in apheresis market:

Fresenius Kabi:

Headquartered at Bad Homburg, Germany, Fresenius Kabi is a global healthcare company specialized in manufacturing and marketing lifesaving technologies for infusion, transfusion and clinical nutrition. The company has global presence with footprint across North America, Europe, Latin America, Asia Pacific, Middle East and Africa markets. The company has a strong focus on R&D across products related to transfusion medicine and cell therapies. In 2020, the company generated USD 8,498.5 million in sales globally. At the beginning of the same year, the company opened a USD 33.46 million transfusion and apheresis disposables plant in Dominican Republic, expressing strong focus on the rising demand for these high-quality disposables.

Terumo BCT, INC:

Terumo Blood and Cell Technologies, familiarly known as Terumo BCT is a U.S. headquartered medical devices company, and a global leader in therapeutic apheresis, blood component and cellular technologies. Originally known as COBE Laboratories, established in 1964, they serve customers across 130 countries. The company is envisioning advancement in automation as a global standard and eyeing at data management, clinical insights and services as next opportunity beyond medical equipment. In April 2020, Terumo BCT and Marker Therapeutics AG jointly received U.S. FDA emergency use authorization for the use of Terumo BCT’s Spectra Optia® Apheresis System and Marker Therapeutics’ D2000 Adsorption Cartridge for treatment of acute respiratory failure in COVID-19 patients.

Asahi Kasei Medical Co. Ltd:

Founded in 1974, Asahi Kasei Medical is a wholly owned subsidiary of Japanese Asahi Kasei Corp. Their primary line of business is development, manufacturing and sale of medical devices, therapeutic apheresis products and dialyzers. With strong product portfolio under plasmapheresis, Asahi Kasei holds a strong market share in global markets with established products, namely, Plasmaflo OP, Cascadeflo EC and IMMUSORBA.

Baxter International INC:

Founded by Drs. Donald Baxter and Ralph Falk, Baxter International is a leading healthcare company, headquartered in Illinois, U.S. Earlier known as Don Baxter Intravenous Products Corporation, the company introduced PLASMA-VAC container, which for first time allowed separation of plasma from whole blood for storage. In November 2020, Baxter Canada received first regulatory approval for their new infusion platform Novum IQ.

Haemonetics Corporation (NYSE:HAE):

Haemonetics Corporation is one of the global leaders in blood management solutions, providing a suite of innovative hematology products and solutions across blood supply chain. The company is strongly positioned in medical markets: blood and plasma component collection, transfusion services and surgical with solutions in the form of medical devices, software and disposables. In October 2020, Haemonetics Corporation received FDA 510(k) clearance for its plasma collection system NexSys PCS® with Persona™ technology.

With rising incidences of cancer and sickle cell disease, cases of accidents and trauma, the demand for apheresis procedures is significant and is expected to rise in the coming years.

Schedule a sample overview of this report